Drug Trial Radar · NCT00176891
Stem Cell Transplant w/Laronidase for Hurler
Last checked: Nov 20, 2026Latest source record: Jul 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Mar 2004
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant.
Conditions
- Mucopolysaccharidosis I
- Hurler Syndrome
Interventions
Stem Cell TransplantProcedure
enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
Laronidase ERTDrug
Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Alive at One Year Post TransplantTime frame: one year
- Number of Patients Requiring Ventilator Support at One Year Post TransplantTime frame: one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.